ABSTRACT
Entecavir is a guanosine nucleoside analog with selective activity against hepatitis B virus (HBV), as well as some activity toward HIV (McMahon et al., 2007). During development it was known as BMS-200475. It is marketed as Baraclude and received regulatory approval in the USA in March 2005, in Australia in April 2006, and in Europe in June 2006.
